Accelerate oncology drug discovery and translational research through Alfa Cytology's custom zebrafish patient-derived xenograft (Z-PDX) model development services, offering an end-to-end integrated pipeline that bridges primary tissue processing, high-precision micro-injection, real-time intra-vital bio-imaging, and robust high-throughput preclinical efficacy evaluation.
Zebrafish patient-derived xenograft (Z-PDX) models represent an advanced translational platform in oncology research, established by transplanting primary human tumor cells directly into early-stage host embryos. This in vivo system bridges the operational gap between traditional cell culture models and mammalian xenografts, leveraging the natural optical transparency, rapid physiological development, and transient immunotolerance of larval hosts. By maintaining the heterogeneous architectural integrity, genetic landscape, cellular microenvironmental interactions, and patient-specific phenotypes of original tumor tissue samples, Z-PDX models provide an efficient, physiologically relevant in vivo host platform for evaluating primary tumor biology, early metastatic dissemination, and dynamic therapeutic responses on significantly accelerated operational timelines.
Fig.1 Zebrafish models for cancer research. (Hason, M., & Bartunek, P., 2019)
Z-PDX platforms provide distinct experimental capabilities that complement and expand conventional mammalian xenograft models, delivering a highly scalable, cost-effective, and rapid in vivo host system for early-stage oncology pipeline acceleration. By capturing patient-specific biological nuances within days rather than months, these models enable rapid iterative testing, early compound triaging, and efficient translation of novel therapeutic strategies.
Rapid Experimental Timelines
Generating actionable xenograft engagement within several days rather than multiple months, thereby drastically shortening compound testing cycles, enabling rapid iterative screening, and accelerating candidate selection during early phase pipeline progression without sacrificing physiological relevance.
Optical Clarity for Real-Time Imaging
Capitalizing on natural embryonic host transparency to perform continuous, high-resolution non-invasive visual tracking of cellular migration, neo-vascularization dynamics, tumor expansion, and dynamic metastatic colonization patterns directly at cellular resolution.
Exceptional Throughput Capacity
Enabling large-scale compound screenings using minimal micro-liter test substance quantities, significantly reducing material consumption while maintaining robust statistical power across large experimental cohorts to evaluate novel therapeutic leads efficiently.
Preservation of Tumor Heterogeneity
Retaining primary patient tumor cell diversity, spatial architectural traits, stromal microenvironmental interactions, and original histological hallmarks without extended in vitro culture adaptation, maintaining faithful reflection of parental tumor phenotypes.
Z-PDX models serve as dynamic, versatile functional assays for investigating complex cancer biological mechanisms and evaluating candidate drug molecules across early-stage preclinical research pipelines. By facilitating direct visualization of cell-matrix interactions, vessel remodeling, and hematogenous dissemination, this platform bridges standard high-throughput cellular screening and downstream mammalian models to streamline lead candidate optimization and pathway profiling.
High-Throughput Drug Candidate Screening
Facilitating parallel testing of small-molecule libraries, biological agents, and novel target compounds against primary tumor material to rapidly identify promising therapeutic candidates.
Assessment of Tumor Angiogenesis
Enabling quantitative visual evaluation of host neo-vascularization dynamics, micro-vessels, and vessel sprouting triggered by human tumor secretomes, accelerating anti-angiogenic target discovery.
In Vivo Metastatic Behavior Mapping
Tracking cell micro-dissemination, extravasation patterns, and tissue colonization across dynamic vascular networks to dissect key physiological drivers of invasive disease.
Evaluation of Combination Therapies
Testing synergistic drug regimens, targeted co-treatments, and multi-agent combinations in vivo to overcome emerging resistance mechanisms efficiently prior to further pipeline development steps.
Drawing on established expertise in zebrafish model development and oncology research, Alfa Cytology offers customizable Z-PDX model development services that integrate tumor engraftment, controlled therapeutic exposure, quantitative imaging, and structured data reporting within a single project framework. The platform is designed around the client's starting material and research question, whether the objective is to establish a new patient-derived model, test a defined set of compounds, or generate functional response data for a cohort of tumor samples. By maintaining the patient-derived character of the tumor material while compressing the experimental timeline, we aim to provide a practical in vivo layer of evidence that informs go/no-go decisions before larger-scale preclinical commitments.
Alfa Cytology delivers specialized model generation tailored to distinct experimental parameters, disease classifications, host genetic backgrounds, and tissue microenvironment requirements. By combining customizable micro-injection protocols with advanced transgenic lines and tailored engraftment strategies, our platform enables researchers to construct highly predictive in vivo disease models that effectively recapitulate key human tumor behaviors, microenvironmental niches, and metastatic cascades.
Models Categorized by Disease Type
Models Categorized by Anatomical Injection Site
Alfa Cytology provides comprehensive, end-to-end analytical services using customized Z-PDX platforms to deliver rapid, reproducible, and multidimensional readouts for oncology research projects. From initial sample handling and xenograft optimization to post-treatment high-content optical imaging and multi-parameter quantitative profiling, our integrated platform supports therapeutic discovery pipelines with reliable, decision-grade in vivo data across streamlined testing schedules.
In Vivo Cytotoxicity & Efficacy Testing
Evaluating compound-induced volume changes, tumor regression rates, and dose-dependent cell death across large cohort larval groups to establish quantitative dose-response relationships, IC50 values, and primary therapeutic efficacy metrics efficiently within tight project schedules.
Anti-Angiogenic Drug Screening
Quantifying host vascular sprouting, sub-intestinal vessel network architecture, and tumor-driven neovascularization dynamics following target compound exposure over fixed temporal windows to characterize anti-angiogenic therapeutic lead candidates.
Invasion & Metastasis Inhibition Assays
Measuring temporal distance, dissemination frequency, and cellular migration pathways from initial injection sites through micro-vascular systems to identify and validate novel anti-metastatic drug candidates and biological inhibitors.
Mechanistic & Pathway Profiling
Dissecting intracellular signaling pathway alterations, target engagement markers, cellular stress pathways, and cell survival mechanisms within tumor grafts following systemic administration of proprietary candidate compounds.
Alfa Cytology's specialized Z-PDX model development services offer an efficient, scalable, and highly reliable translational platform designed to accelerate candidate selection and unlock deep functional insights into tumor biology. By integrating tailored model design, specialized micro-injection techniques, continuous optical tracking, and comprehensive bio-image quantification, we support biopharmaceutical teams in advancing innovative oncology projects efficiently. Contact our technical scientific team today to explore customized model parameters, review assay design options, or initiate your next-generation preclinical study framework.
Reference
For research use only.
Alfa Cytology, a preclinical research solution provider, provides its clients with one-stop solutions to accelerate cancer therapeutics discovery and development.
Copyright © 2026 Alfa Cytology. All rights reserved.